ADAM17 and colorectal carcinoma: In particular, the ADAM17 inhibitor ZLDI-8 inhibits the proliferation of CRC and improves the anti-tumor and anti-metastasis activity of 5-fluorouracil (5-FU) or irinotecan by reversing Notch and EMT pathways, both in vitro and in vivo [197].